[서울=뉴스핌] Journalist Yohan Bae = AP Technology, a corporation specializing in the manufacturing of human milk oligosaccharides (HMOs), announced on the 31st that it has attained a patent for a composition for the prevention and treatment method of muscle atrophy and sarcopenia made up of oligosaccharides of the human milk.
In accordance to the rehabilitation drugs sector, about 10% of the inhabitants over 65 in Korea are identified with sarcopenia. When the Asian diagnostic conditions are utilized, 21.3% of males and 13.8% of girls among the the elderly in excess of 70 many years of age are patients with sarcopenia. There are an believed 8.5 million people today over the age of 65 in Korea and 800,000 people with sarcopenia.
Muscle atrophy / sarcopenia is prompted by results in of getting older these types of as ▲ absence of mechanical stimulation, ▲ getting old of astrocytes, ▲ decline in mitochondrial function, ▲ stroke, ▲ chronic ailment, ▲ drug overuse, and many others. As symptoms worsen, the assortment of blood glucose fluctuations because of to insulin resistance boosts and is challenging to control, which improves the incidence of several disorders such as diabetic issues, hyperlipidemia, weakened immunity and joint illness.
The composition for prevention and treatment that contains 2′-FL shows the impact of growing mitochondrial functionality which regulates the advancement of muscle mass mass and muscle strength and increasing the expression of genes relevant to mitochondrial biosynthesis. This cuts down the expression of factors involved in muscle mass atrophy and sarcopenia, thereby rising muscle toughness and protecting against muscle mass atrophy and sarcopenia.
2′-FL is the most crucial part of human milk oligosaccharide (HMO), which is present only in breast milk, and performs functions such as the development of a useful microbiome, excretion of the virus, immune activation and mind cell progress. Not too long ago, it has captivated notice as a big factor affecting the immune system. With this patent, 2′-FL was found to be efficient in sarcopenia and the area of adaptation is expected to broaden additional in the upcoming.
“By this patent acquisition, we have confirmed the likelihood that 2′-FL will be a new alternate to strengthen sarcopenia,” mentioned an AP Technological know-how formal.
–
